KYNTRA BIO, INC.

KYNTRA BIO, INC. (KYNB) is a publicly listed company on US equity markets.

Kyntra Bio Inc is a biopharmaceutical company focused on the development of novel therapies in oncology and rare disease. The company's research programs target cancer and rare disease indications, including anemia associated with lower-risk myelodysplastic syndrome (LR-MDS) and metastatic castration-resistant prostate cancer (mCRPC). Itd pipeline drug candidates include Roxadustat and FG-3246.

The company reports trailing twelve-month revenue of $6.44M and net loss of $15.20M.

Key metrics include a return on equity of 34.7%, a debt-to-equity ratio of -2.71.

Use FINOTAUR to track KYNB's price action, review fundamentals, and stay current with company news — all in one research dashboard.